[勘误：克唑替尼治疗lorlatinib耐药met扩增eml4 - alk融合阳性晚期肺腺癌1例报告]。

Q4 Medicine

中国肺癌杂志 Pub Date : 2025-03-20 DOI:10.3779/j.issn.1009-3419.2025.103.01

引用次数: 0

摘要

这更正了文章DOI: 10.3779/j.issn.1009-3419.2024.102.37。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[Erratum: Crizotinib Treatment for Lorlatinib-resistant MET-amplified EML4-ALK-fusion Positive Advanced Lung Adenocarcinoma: A Case Report].

This corrects the article DOI: 10.3779/j.issn.1009-3419.2024.102.37.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中国肺癌杂志 Medicine-Pulmonary and Respiratory Medicine

CiteScore

1.40

自引率

0.00%

发文量

5131

审稿时长

14 weeks

期刊介绍： Chinese Journal of Lung Cancer(CJLC, pISSN 1009-3419, eISSN 1999-6187), a monthly Open Access journal, is hosted by Chinese Anti-Cancer Association, Chinese Antituberculosis Association, Tianjin Medical University General Hospital. CJLC was indexed in DOAJ, EMBASE/SCOPUS, Chemical Abstract(CA), CSA-Biological Science, HINARI, EBSCO-CINAHL,CABI Abstract, Global Health, CNKI, etc. Editor-in-Chief: Professor Qinghua ZHOU.